Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Dang NH, et al. Among authors: castaigne s. Br J Haematol. 2018 Aug;182(4):583-586. doi: 10.1111/bjh.14820. Epub 2017 Jul 5. Br J Haematol. 2018. PMID: 28677896 Free PMC article. Clinical Trial. No abstract available.
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.
Pautas C, Raffoux E, Lambert J, Legrand O, Chantepie S, Gastaud L, Marolleau JP, Thomas X, Turlure P, Benner RJ, Vandendries E, Gogat K, Dombret H, Castaigne S. Pautas C, et al. Among authors: castaigne s. Bone Marrow Transplant. 2021 Jun;56(6):1474-1477. doi: 10.1038/s41409-020-01207-4. Epub 2021 Feb 9. Bone Marrow Transplant. 2021. PMID: 33564120 Free PMC article. Clinical Trial.
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.
Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Farhat H, et al. Among authors: castaigne s. Am J Hematol. 2012 Jan;87(1):62-5. doi: 10.1002/ajh.22201. Epub 2011 Nov 10. Am J Hematol. 2012. PMID: 22072535 Free article. Clinical Trial.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Lambert J, et al. Among authors: castaigne s. Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076173 Free PMC article. Clinical Trial.
Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).
Bastie JN, Suzan F, Garcia I, Isnard F, de Revel T, Terre C, Mayeur D, Abraham C, Lavielle R, Castaigne S. Bastie JN, et al. Among authors: castaigne s. Br J Haematol. 2002 Mar;116(4):924. doi: 10.1046/j.0007-1048.2002.03346.x. Br J Haematol. 2002. PMID: 11886404 Free article. No abstract available.
Long-term complete haematological and molecular remission after allogeneic bone marrow transplantation in a patient with a stem cell myeloproliferative disorder associated with t(8;13)(p12;q12).
Suzan F, Guasch G, Terre C, Garcia I, Bastie JN, Maarek O, Ribaud P, Gluckman E, Daniel MT, Pébusque MJ, Castaigne S. Suzan F, et al. Among authors: castaigne s. Br J Haematol. 2003 Apr;121(2):312-4. doi: 10.1046/j.1365-2141.2003.04269.x. Br J Haematol. 2003. PMID: 12694254 Free article.
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.
De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P; European APL Group. De Botton S, et al. Among authors: castaigne s. Br J Haematol. 2000 Dec;111(3):801-6. doi: 10.1046/j.1365-2141.2000.02442.x. Br J Haematol. 2000. PMID: 11122141 Free article. Clinical Trial.
200 results